| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Sagimet Biosciences Inc. - Series A$7.37
+0.02 (+0.27%)
C 52Pipeline Score Fair Value Pharma · Clinical
Market Cap
433.80 M
EPS
-1.34
P/E Ratio
-
Value Trade
4.50 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
7.00 M
Operating CF
-8.61 M
Total Assets
107.75 M
Total Liabilities
107.75 M
Equity
102.46 M
D/E Ratio
12,345
-2.34 %
Week
17.19 %
1 Month
32.03 %
3 Month
3.5 %
6 Month
-54.26 %
5 Year
-54.26 %
All Time
Cash Data
Cash Position
104.54 M
Monthly Burn
2.87 M
Runway
34.7 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.11 M
52 Week Range
3.32 - 11.41
% held by Insiders
5.12 %
% held by Institutions
20.77 %
Enterprise Value
329.30 M
Total Shares
32.03 M
Short %
29.21 %
Float Shares
28.25 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sagimet Biosciences Inc. - Series A
144Total events
8Upcoming
46Tier-1 (high impact)
2022 – 2028Coverage
Upcoming catalysts 8
Jul 15, 2026
T2R&D Day
Management to participate in 1x1 investor meetings at Leerink Partners Therapeutics Forum
Dec 2026
T2Milestone Payment
Complete development and regulatory activities for denifanstat-resmetirom combination Phase 2 readiness
TBD
T2Oral Presentation
Data from open-label Phase 3 trial planned to be shared in upcoming congresses
Event history 136
Q3 2026
◆Trial InitiationTVB-3567Trial
Phase 2 clinical trial with TVB-3567 in moderate to severe acne planned to initiate
moderate to severe acnesource ↗
Q3 2026
▲IND ClearancedenifanstatIND
IND clearance for denifanstat in moderate to severe acne
moderate to severe acnesource ↗
Q3 2026
◆Trial InitiationdenifanstatTrial
Initiate U.S. Phase 3 clinical trial of denifanstat in moderate to severe acne
moderate to severe acnesource ↗
Jun 22, 2026
▼Equity OfferingCorporate
Inducement grant of 34,300 stock options to two new employees under Nasdaq Rule 5635(c)(4)
Jun 2026
●IND SubmissiondenifanstatIND
IND submission for denifanstat in moderate to severe acne
moderate to severe acnesource ↗
May 30, 2026
▲Poster PresentationdenifanstatPresentation
Poster presentation at EASL 2026: Transcriptomic analysis of FASN inhibitor and resmetirom combination in LDL receptor knockout MASH mice
MASHsource ↗
May 27, 2026
▲Poster PresentationdenifanstatPresentation
Poster presentation at EASL 2026: Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial (Best of EASL)
MASHsource ↗
May 15, 2026
◆Poster PresentationPresentation
Poster presentation at SID 2026 on FASN inhibitors reducing sebum lipids in human sebocytes
acnesource ↗
Apr 27, 2026
▼Equity OfferingCorporate
Pricing of $175.0 million underwritten offering of Series A common stock at $6.00 per share
Apr 20, 2026
Drug Pipeline Intelligence
C52
Pipeline Score $578M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.3x
rNPV / MCap Top 78%
Micro Cap (rank 201 of 911)
Percentile RankSagimet Biosciences Inc. - Series A carries a moderate pipeline score (52/100), with $1.4B risk-adjusted pipeline value, led by TVB-2640 in Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVB-2640 Small molecule | KRAS Gene Mutation | Phase 2 | NCT03808558 | 27% | $812M | ACTIVE NOT_RECRUITING | 18 | - | - | Dec 1, 2026 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
denifanstat/resmetirom Breakthrough | MASH and liver fibrosis | Phase 1 | 2026-05-27 | Cohort 1: total cholesterol -23mg/dl, LDL cholesterol -17mg/dl; Cohort 2: total cholesterol -16mg/dl, LDL cholesterol -14mg/dl; p value: <0.001 Read More | Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH Read More | |
denifanstat/resmetirom Breakthrough | MASH and liver fibrosis | Phase 1 | 2026-05-27 | Cohort 1: total cholesterol -23mg/dl, LDL cholesterol -17mg/dl; Cohort 2: total cholesterol -16mg/dl, LDL cholesterol -14mg/dl; p value: <0.001 Read More | Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH Read More | |
denifanstat/resmetirom Breakthrough | MASH and liver fibrosis | Phase 1 | 2026-05-27 | Cohort 1: total cholesterol -23mg/dl, LDL cholesterol -17mg/dl; Cohort 2: total cholesterol -16mg/dl, LDL cholesterol -14mg/dl; p value: <0.001 Read More | Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SGMT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SGMT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SGMT▲ +10.3%on this news
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
Sagimet Biosciences has been added to the Russell 2000 and 3000 indexes, effective immediately. This inclusion reflects the company's progress and is expected to enhance its visibility in the market. Sagimet plans to initiate a Phase 3 clinical trial for denifanstat, targeting moderate to severe acne, later this year. If successful, denifanstat could be the first new oral treatment for acne in over forty years.
Read more →SGMTSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences has announced its participation in the upcoming Leerink Partners Therapeutics Forum in Boston on July 15, 2026. Additionally, the company approved an inducement grant of 34,300 stock options to two newly hired employees as part of their compensation. This grant aligns with Nasdaq Rule 5635(c)(4) and aims to attract talent to support Sagimet's development of novel therapeutics targeting metabolic and fibrotic pathways.
Read more →SGMTSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Sagimet Biosciences presented two posters at EASL 2026, showcasing Phase 1 clinical data on the combination of denifanstat and resmetirom. The combination therapy demonstrated rapid reductions in cholesterol levels and was generally well-tolerated. This research highlights the potential cardiovascular benefits and therapeutic efficacy for MASH and liver fibrosis.
Read more →SGMTSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Sagimet Biosciences will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with management, showcasing their novel therapeutics targeting metabolic and fibrotic pathways. A webcast of the chat will be available on their website.
Read more →SGMTSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences reported its financial results for Q1 2026, highlighting a successful $175 million equity financing. The company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in the second half of 2026. Additionally, a Phase 1 trial of the FASN inhibitor TVB-3567 is ongoing, with expectations to fund operations through 2028.
Read more →SGMTSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences announced it will present data at the Society for Investigative Dermatology Annual Meeting, showcasing the potential of FASN inhibitors in treating acne. The pre-clinical studies indicated that these inhibitors reduce sebum production, a key factor in acne development. A Phase 3 clinical trial for denifanstat is set to begin in late 2026.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Sagimet Biosciences has announced the pricing of an underwritten offering of 29.17 million shares of its Series A common stock at $6.00 per share, aiming to raise approximately $175 million. The proceeds will primarily fund a Phase 3 clinical trial for denifanstat in acne and support other clinical developments. The offering is set to close on or about April 28, 2026.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1shared move
Sagimet Biosciences Provides Strategic and Corporate Updates
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in late 2026, following positive results from a trial in China. The company is also conducting a Phase 1 trial for another FASN inhibitor, TVB-3567. Development for MASH will be paused until non-dilutive funding is secured. Sagimet will host a KOL event on April 30, 2026, to discuss its acne treatment plans.
Read more →SGMT▲ +38.6%on this news· ran to +49% by day 1shared move
Targeting MetabolicDysfunction with Novel Therapeutics April 2026 April 2026 2 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to t
Sagimet Pharma is advancing its clinical programs for two promising therapeutics: TVB-3567 and denifanstat. TVB-3567 is currently in a Phase 1 trial for moderate to severe acne, with plans for a Phase 2 trial anticipated in 2026. Denifanstat has shown positive results in Phase 2b trials for metabolic dysfunction-associated steatohepatitis (MASH) and a significant combination therapy with resmetirom is in development. Safety and efficacy of denifanstat were well-demonstrated across clinical trials, prompting the company to explore further study in MASH and acne.
Read more →SGMTSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Sagimet Biosciences has appointed Dr. Andreas Grauer as Chief Medical Officer, effective April 20, 2026. Dr. Grauer brings over two decades of experience in clinical development and medical affairs, previously serving as CMO at Omeros Corporation. He will lead the clinical development of Sagimet's FASN inhibitors, while former CMO Eduardo Martins transitions to an advisory role.
Read more →SGMTSagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences announced that it will present findings from the Phase 2b FASCINATE-2 trial of denifanstat at the Fueling MASH Symposium in Vancouver. The trial demonstrated significant reductions in bile acids in patients responding to treatment. Additionally, the company granted stock options to a new employee under Nasdaq rules.
Read more →SGMTSagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial
Sagimet Biosciences has reported its financial results for the fourth quarter and full year of 2025, highlighting significant progress in its clinical development programs. The company successfully completed a Phase 1 pharmacokinetic clinical trial of the denifanstat and resmetirom combination and plans to advance it into a Phase 2 trial targeting F4 MASH patients, a population for which no approved treatments exist. Additionally, the company's NDA for denifanstat in treating acne has been accepted by the Chinese regulatory authority. Despite these advancements, the company continues to face financial challenges.
Read more →SGMTSagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Sagimet Biosciences has announced its participation in three upcoming investor conferences, showcasing its commitment to engaging with the investment community. The company is known for developing novel therapeutics, particularly FASN inhibitors, which have shown promising results in clinical trials. Notably, denifanstat has met all primary endpoints in its Phase 2b trial and is being further developed for various conditions.
Read more →SGMT▼ -10.5%on this news
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. announced its participation in two upcoming investor conferences, including Guggenheim and Oppenheimer fireside chats. The events will be accessible via the company's website, with replays available for 90 days. Sagimet is known for its clinical-stage development of novel FASN inhibitors, with promising results in recent trials.
Read more →SGMT▲ +9.9%on this newsshared move
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Sagimet Biosciences announced positive results from Ascletis Pharma's Phase 3 trial of ASC40 (denifanstat) for moderate to severe acne. The open-label study showed that denifanstat was well tolerated and improved efficacy endpoints over 52 weeks. This trial builds confidence in FASN inhibition as a novel treatment mechanism for acne.
Read more →SGMT▼ -8.5%on this newsshared move
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
Ascletis Pharma announced positive topline results from a Phase III open-label study of denifanstat (ASC40), a first-in-class oral fatty acid synthase inhibitor for moderate-to-severe acne. The study demonstrated favorable safety and tolerability in 240 patients, with no serious adverse events reported. The drug's unique mechanism targets the underlying causes of acne, setting it apart from existing treatments.
Read more →SGMTBiotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
CancerVax, Inc. has appointed Dr. George Kemble as Senior Scientific Advisor to enhance its cancer treatment platform. Dr. Kemble, a seasoned biotech executive with a strong background in virology and vaccine development, will guide the company's innovative approach to using the immune system against cancer. His expertise is expected to significantly contribute to the advancement of CancerVax's unique treatment strategies.
Read more →SGMTSagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Read more →SGMTTargeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer December 2025 December 2025 2 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the mean
Sagimet's lead molecule, denifanstat, is a fatty acid synthase inhibitor showing potential in treating metabolic dysfunction-associated steatohepatitis (MASH) and acne. Recent trials have demonstrated significant efficacy, including a Phase 2b trial that met key endpoints for MASH. The company is advancing its second FASN inhibitor, TVB-3567, preparing for a Phase 2 trial in acne following successful Phase 1 outcomes. However, the cessation of the GBM program poses challenges in developing treatments for glioblastoma.
Read more →SGMTSagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
Read more →SGMTSagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
Sagimet Biosciences has entered a global license agreement with TAPI for innovative forms of resmetirom, which will be used in a fixed-dose combination product with denifanstat. This collaboration aims to enhance treatment options for patients with metabolic dysfunction-associated steatohepatitis (MASH). A Phase 1 trial is currently underway, with results expected by the end of 2025.
Read more →SGMTSagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Sagimet Biosciences announced that Ascletis Pharma's New Drug Application for denifanstat has been accepted by China's NMPA for treating moderate to severe acne. Denifanstat, a fatty acid synthase inhibitor, has shown positive results in clinical trials, meeting all endpoints. This development marks a crucial step for Sagimet's collaboration with Ascletis in the Chinese market.
Read more →SGMTAscletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Read more →SGMTSagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences announced the approval of inducement grants for three new employees, totaling 42,800 stock options. These options, granted under Nasdaq Rule 5635(c)(4), are part of the employees' compensation and will vest over four years. Sagimet continues to develop innovative therapeutics targeting metabolic and fibrotic pathways.
Read more →SGMT▼ -7.4%on this news
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025. The event will feature a fireside chat with management at 12:55 PM ET. Sagimet is known for its development of novel FASN inhibitors aimed at treating metabolic and fibrotic conditions, with promising results from its clinical trials.
Read more →SGMT▼ -12.2%on this news
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences reported its financial results for Q3 2025 and highlighted ongoing clinical trials. The company is conducting a Phase 1 trial for a combination of denifanstat and resmetirom, with results expected in 1H 2026. Additionally, a first-in-human Phase 1 trial for TVB-3567 is underway, targeting acne treatment. Sagimet aims to explore FASN inhibition's potential across various indications.
Read more →SGMT▲ +10.8%on this newsshared move
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
Sagimet Biosciences presented two posters at AASLD 2025 highlighting denifanstat's efficacy in treating advanced fibrosis in MASH patients. The first poster detailed a secondary analysis from the Phase 2b FASCINATE-2 trial, showing significant improvements in fibrosis and inflammation. The second poster utilized spatial computational histology to predict treatment responses, underscoring the potential of AI in clinical assessments.
Read more →SGMT▲ +24.7%on this news
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Sagimet Biosciences announced that denifanstat achieved all primary and secondary endpoints in a Phase 3 clinical trial for moderate to severe acne in China. The trial, conducted by Ascletis, demonstrated significant improvements in treatment success rates compared to placebo. Following the trial, Ascletis plans to submit a New Drug Application to the NMPA for denifanstat.
Read more →SGMTTargeting MetabolicDysfunction with Novel Therapies to Treat MASH, Acne&Cancer October 2025 October 2025 2 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meanin
Ascletis is advancing its lead molecule denifanstat, a fatty acid synthase inhibitor, which is showing positive outcomes in treating metabolic dysfunction-associated steatohepatitis (MASH) and acne. The drug is in Phase 1 and Phase 2 trials for various applications, with significant clinical data supporting its success. Additionally, the company is developing TVB-3567 as a follow-on FASN inhibitor with plans to start a Phase 2 trial in acne. However, the cessation of the GBM program represents a strategic setback for Ascletis.
Read more →SGMTAscletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Read more →SGMTSagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Sagimet Biosciences announced that data from the Phase 2b FASCINATE-2 study of denifanstat will be presented at AASLD 2025. The study demonstrated significant fibrosis improvement in patients with advanced fibrosis. Denifanstat's anti-fibrotic effects were validated using both conventional and AI-based digital pathology. The drug has received Breakthrough Therapy designation from the FDA.
Read more →SGMTSagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
Sagimet Biosciences has commenced dosing participants in a Phase 1 pharmacokinetic trial for its combination therapy of denifanstat and resmetirom. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of the drugs in healthy adults. If successful, the results will guide further development for patients with metabolic dysfunction-associated steatohepatitis (MASH). Topline data is expected in early 2026.
Read more →SGMT▲ +8.2%on this news
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
Sagimet Biosciences Inc. announced its participation in a drug development panel at Fierce Biotech Week from October 7-9, 2025, in Boston. The company is known for developing FASN inhibitors, particularly denifanstat, which has shown positive results in a Phase 2b trial for MASH. Denifanstat has also received Breakthrough Therapy designation from the FDA, facilitating its further development.
Read more →SGMTPositive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Sagimet Biosciences announced that denifanstat achieved positive results in a Phase 3 clinical trial for moderate to severe acne, meeting all primary and secondary endpoints. The data will be presented at the EADV Congress 2025. Denifanstat, a fatty acid synthase inhibitor, was well tolerated in the trial, which included 480 patients.
Read more →SGMTAscletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Read more →SGMTSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
Sagimet Biosciences announced its participation in the 9th Annual MASH Drug Development Summit, where it will present two oral presentations and join a drug development panel. The presentations will focus on a FASN inhibitor combination treatment and AI-based digital pathology for evaluating denifanstat's anti-fibrotic effects in MASH patients. The company has also successfully completed a Phase 2b trial for denifanstat, which has received Breakthrough Therapy designation from the FDA.
Read more →SGMTSagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. is set to participate in two major investor conferences in New York, showcasing its ongoing developments. The company has announced its participation in the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference in September 2025. This comes amid successful clinical developments, including the completion of a Phase 2b trial for its lead drug candidate, denifanstat, which also received Breakthrough Therapy designation from the FDA for metabolic dysfunction treatment. Sagimet is also advancing a second drug candidate planned for acne treatment.
Read more →SGMTSagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by licen
Sagimet Biosciences reported strong advancements in its clinical pipeline, including positive Phase 3 results for denifanstat in treating moderate to severe acne, conducted by its partner Ascletis. The company has also initiated a Phase 1 clinical trial for another FASN inhibitor, TVB-3567, for acne treatment in the U.S. Forward-looking statements indicate plans for further trials, including a combination therapy for MASH. Despite this progress, Sagimet faces financial challenges, as evidenced by its recent operating losses.
Read more →SGMT▲ +6%on this news
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Read more →SGMTSagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne' on June 16, 2025
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne' on June 16, 2025
Read more →SGMT▲ +12.4%on this news· ran to +47% by day 3shared move
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was
Sagimet Biosciences has announced successful Phase 3 trial results for Denifanstat, a fatty acid synthase (FASN) inhibitor, demonstrating efficacy in treating moderate-to-severe acne. The trial, conducted by Ascletis in China, met all primary and secondary endpoints, showing significant improvements in lesion counts compared to placebo. Denifanstat was well tolerated, with adverse events being mild to moderate. In addition to Denifanstat, Sagimet has initiated a Phase 1 trial for another FASN inhibitor, TVB-3567, indicating the company's commitment to innovating treatments in the acne space.
Read more →SGMTAscletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Read more →SGMT▲ +5.9%on this news
Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Read more →SGMTSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to init
Sagimet Biosciences announced its first quarter 2025 financial results and corporate updates, highlighting the anticipated initiation of a Phase 1 clinical trial for a combination therapy of denifanstat and resmetirom in the second half of 2025. Positive findings from the Phase 2b FASCINATE-2 trial bolster the company's outlook for addressing metabolic dysfunction associated steatohepatitis (MASH). However, the financial loss and rising development costs could pose challenges to its ongoing ventures.
Read more →SGMT▲ +8.8%on this news· ran to +30% by day 3
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
Read more →SGMTSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Break
Sagimet Biosciences has reported its financial results for the year 2024, highlighting the initiation of its Phase 3 MASH program for denifanstat and receiving Breakthrough Therapy designation from the FDA. The company also provided updates on another drug candidate, TVB-3567, which has received IND clearance for clinical development targeting acne. Despite these advancements, Sagimet faced a significant net loss of $45.6 million for the year, alongside rising operating expenses, which raised concerns about its financial sustainability in the near future.
Read more →SGMTSagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial ini
Sagimet Biosciences has announced the clearance of its Investigational New Drug application for TVB-3567, its second fatty acid synthase inhibitor aimed at treating acne. This clearance allows for the initiation of a first-in-human Phase 1 clinical trial planned for 2025. The compound has shown promising results in prior programs, particularly in altering sebum composition, which is key in acne treatment. The company anticipates that TVB-3567 could offer a differentiated approach to managing acne, a condition affecting over 50 million individuals in the U.S.
Read more →SGMTSagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Read more →SGMTTargeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer February 2025 2 February 2025 Forward - Looking Statements and Disclaimer This presentation contains forward - looking statements within
Sagimet is focusing on metabolic dysfunction with its lead molecule, denifanstat, which is a unique FASN inhibitor. The drug is currently in Phase 3 trials for multiple indications, including metabolic dysfunction associated with steatohepatitis (MASH) and acne. Positive results from previous clinical trials have encouraged advancements, and the company has received an FDA designation to expedite the clinical development process. The leadership team boasts extensive experience in biotech and pharma, enhancing confidence in the company's progression.
Read more →SGMT▲ +36.4%on this news
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Read more →SGMTTargeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer January 2025 2 January 2025 Forward Looking Statements This presentation contains forward - looking statements within the meaning of, and
Sagimet's lead drug candidate, denifanstat, is a novel fatty acid synthase (FASN) inhibitor aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), acne, and cancer. Denifanstat has received FDA Breakthrough Therapy designation for MASH and is progressing through Phase 3 trials. The company's recent presentation outlines the management's strong track record and the potential growth opportunities across multiple therapeutic areas, despite acknowledging various risks and uncertainties in clinical development. Key milestones include expected topline results for acne in mid-2025 and the initiation of Phase 3 for MASH anticipated in early 2025.
Read more →SGMTSagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Read more →SGMT▼ -7.8%on this news
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024
Read more →SGMT▼ -14%on this news· ran to -27% by day 3shared move
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanst
Sagimet Biosciences has reported its financial results for the third quarter of 2024, showing a net loss of $14.6 million. The company has received Breakthrough Therapy designation from the FDA for its lead drug candidate, denifanstat, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). Additionally, positive results from the Phase 2b FASCINATE-2 study were published in The Lancet, bolstering expectations for the Phase 3 program set to begin by the end of 2024. Sagimet's financial position reflects $170.0 million in cash and marketable securities as of September 30, 2024.
Read more →SGMTAscletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Read more →SGMTSagimet Biosciences to Participate in the UBS Global Healthcare Conference
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
Read more →SGMTSagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Read more →SGMT▲ +6.4%on this news
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024
Read more →SGMTSagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Read more →SGMT▲ +12.6%on this news· ran to +48% by day 3
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Read more →SGMT▲ +12.6%on this news· ran to +48% by day 3
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →SGMT▼ -9.6%on this news
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Read more →SGMT▼ -7.1%on this news
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Read more →SGMTSagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Read more →SGMTSagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Stud
Sagimet Biosciences has reported its second-quarter financial results for 2024, showcasing significant advancements in its Phase 2b FASCINATE-2 clinical trial, which demonstrated promising results for its lead drug denifanstat against metabolic dysfunction-associated steatohepatitis (MASH). With the aim to initiate a Phase 3 clinical development program later this year, the company also highlighted a strong cash position with $188.5 million available to fund its operations through 2025. Additionally, the appointment of two industry leaders to its Board of Directors represents a strategic enhancement of the company’s leadership team. Sagimet faces ongoing challenges, including reported net losses, as it navigates the complexities of clinical trial developments.
Read more →SGMT▼ -7.3%on this news
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer July 2024 2 July 2024 Forward Looking Statements This presentation contains forward - looking statements within the meaning of, and made
Sagimet is advancing its lead drug, denifanstat, aimed at treating metabolic dysfunction associated with steatohepatitis (MASH), acne, and cancer. The Phase 2b trial has reported positive results, showing improvements in liver fibrosis, which positions denifanstat as a unique metabolic therapy. The company is also collaborating with Ascletis for further development, with a robust patent portfolio supporting its commercialization. However, clinical trial uncertainties and reliance on partnerships add inherent risks to their future outcomes.
Read more →SGMT▼ -10.3%on this news· ran to -26% by day 3
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 Denifanstat achieved statistically significant results
Sagimet Biosciences has reported encouraging data from its Phase 2b FASCINATE-2 clinical trial of denifanstat, presented at the EASL International Liver Congress 2024. The trial indicates that denifanstat achieved significant improvement in liver fibrosis levels among patients with metabolic dysfunction-associated steatohepatitis (MASH) without worsening their condition. Specifically, the drug demonstrated statistically significant results for both primary and secondary endpoints, including notable improvements in fibrosis stages. Safety data indicates that denifanstat was generally well tolerated with no severe adverse effects reported.
Read more →SGMTSagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Read more →SGMT▼ -7.5%on this news
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne and Cancer May 202 4 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursuant
Sagimet is targeting metabolic dysfunction with novel therapies, specifically denifanstat, aimed at treating MASH, acne, and cancer. Recent positive topline results from Phase 2b trials have demonstrated its potential in MASH, along with established clinical proof of concept in acne and ongoing trials for cancer. The company has successfully raised significant funds, positioning it strongly for future developments in these therapeutic areas. However, there are risks associated with the clinical development and potential variability in trial outcomes.
Read more →SGMTSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Read more →SGMT▲ +5.5%on this newsshared move
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congr
Sagimet Biosciences reported its financial results for Q1 2024, highlighting the successful completion of the Phase 2b FASCINATE-2 trial for denifanstat, which met key efficacy endpoints. The company noted a significant cash position of $193.7 million, ensuring operations through 2025. Anticipated milestones include an oral presentation of trial data at the EASL International Liver Congress and a planned initiation of a Phase 3 trial in 2024 following FDA meetings. The focus remains on advancing denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Read more →SGMTSagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Read more →SGMTSagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
Read more →SGMTSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Read more →SGMT▲ +9.6%on this news
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
Read more →SGMT▲ +15.7%on this newsshared move
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne and Cancer March 202 4 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursua
Sagimet has presented forward-looking statements regarding its novel therapies targeting metabolic dysfunction related to MASH, acne, and cancer. The company reported encouraging results from Phase 2 trials for both MASH and acne. Denifanstat, their FASN inhibitor, showed positive outcomes and is advancing towards a Phase 3 study for MASH, demonstrating promise in treating an underserved patient population. However, there remain uncertainties related to future clinical trial results and necessary regulatory procedures.
Read more →SGMT▲ +15.7%on this newsshared move
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Read more →SGMT▲ +15.7%on this newsshared move
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Read more →SGMT▼ -13.6%on this news· ran to -36% by day 3
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock 01/25/2024 at 8:58
Sagimet Biosciences Inc. has announced the pricing of its public offering of Series A common stock, selling 9,000,000 shares at $12.50 each, expected to generate $112.5 million in gross proceeds. The offering, which is scheduled to close on January 30, 2024, is aimed at supporting the company's clinical development of novel fatty acid synthase inhibitors. Notably, its lead candidate, denifanstat, has shown promise in treating NASH, with positive results from the FASCINATE-2 Phase 2b trial.
Read more →SGMTSagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
Read more →SGMT▲ +170.1%on this newsshared move
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Read more →SGMT▲ +170.1%on this newsshared move
Targeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer January 202 4 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursu
Sagimet is advancing novel therapies aimed at treating metabolic dysfunction related to NASH, acne, and cancer. Their leading candidate, denifanstat, has shown positive results in Phase 2b trials for NASH, demonstrating significant improvements in liver fat and fibrosis. The company has completed an upsized IPO, raising $96.4 million and has sufficient funding for operations through Q1 2025. However, the potential for future trials to yield unfavorable data and the competitive landscape present risks for Sagimet's developmental progress.
Read more →SGMT▲ +170.1%on this newsshared move
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Read more →SGMT▼ -8%on this news
Targeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer December 2023 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursu
Sagimet Medical's presentation highlights its strategic focus on targeting metabolic dysfunction through innovative therapies to treat conditions such as NASH, acne, and cancer. The company provides updates on its progressive clinical trials, specifically pointing out significant improvements in biomarkers related to NASH and positive Phase 2 results for acne treatments. Their financial health is bolstered by a recent IPO that raised substantial funds. However, there are associated risks linked to their forward-looking statements and reliance on third-party collaborations, which may affect future outcomes.
Read more →SGMT▲ +7.1%on this news
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
Read more →SGMTSagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
Read more →SGMT▲ +13.6%on this news· ran to +27% by day 1shared move
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
Read more →SGMT▼ -13.7%on this news
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarte
Sagimet Biosciences has reported its financial results for the third quarter of 2023, noting significant revenues from a licensing agreement and continued development of its lead drug candidate, denifanstat. The company anticipates key topline week 52 liver biopsy results from the Phase 2b FASCINATE-2 trial for NASH in early 2024. Although the financial outlook shows a growing net loss, current cash and asset levels provide some buffer. The advancements in both oncology and acne treatment are also highlighted as part of their diversification strategy.
Read more →SGMT▼ -7.7%on this news· ran to -20% by day 1shared move
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023
Read more →SGMTSagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023
Read more →SGMT▼ -8.1%on this newsshared move
Targeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer October 2023 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursua
Sagimet is focusing on developing denifanstat, a FASN inhibitor, to treat metabolic diseases including NASH, acne, and cancer. The firm has reported statistically significant improvements in key biomarkers during its Phase 2b trial for NASH, with results expected in early 2024. Despite positive indicators, the company acknowledges various risks associated with clinical trials and the unpredictable nature of forward-looking statements. The recently completed IPO has provided a strong financial foundation for its upcoming clinical endeavors.
Read more →SGMTSagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
Read more →SGMTSagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
Read more →SGMTTargeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer September 27 , 2023 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made
Sagimet Therapeutics is advancing the development of denifanstat, an FASN inhibitor targeting metabolic dysfunction associated with NASH, acne, and cancer. The company reported positive interim results from its Phase 2b clinical trial, indicating significant biomarker improvements in NASH. Additionally, an upsized IPO has bolstered their financial position, with clear funding projected through early 2025. However, the company acknowledges inherent risks linked to drug development and the uncertainties surrounding predictive statements.
Read more →SGMTSagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress
Sagimet Biosciences has reported its financial results for the second quarter of 2023, highlighting the successful completion of an upsized initial public offering that raised $96.4 million. The company provided updates on its Phase 2b FASCINATE-2 trial for its lead drug candidate, denifanstat, which showed positive interim results at the EASL Congress. Additionally, Sagimet expects to report week 52 liver biopsy results in the first quarter of 2024. The company has also made leadership changes with new appointments in its executive team.
Read more →SGMTSagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
Read more →SGMTTargeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer August 2023 Forward Looking Statements 2 This presentation contains forward - looking statements within the meaning of, and made pursuan
Sagimet's presentation discusses the development of denifanstat, an FASN inhibitor, targeting metabolic dysfunction in NASH, acne, and cancer. The drug has shown positive interim results in the FASCINATE-2 Phase 2b trial, with significant improvements in liver fat, inflammation, and fibrosis associated with NASH. The company emphasized its strong financial standing, bolstered by a recent IPO, while cautioning about the uncertainties inherent in clinical trial outcomes and regulatory processes.
Read more →SGMTSagimet Biosciences Announces Leadership Changes
Sagimet Biosciences Announces Leadership Changes
Read more →SGMTSagimet Biosciences Announces Pricing of Upsized Initial Public Offering
Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
Read more →SGMTSagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023
Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023
Read more →SGMTSagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
Read more →SGMTPhase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Read more →SGMTSagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients
Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients
Read more →SGMTSagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD's The Liver Meeting
Sagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD's The Liver Meeting
Read more →SGMTSagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role
Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role
Read more →SGMTFASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Read more →SGMTSagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b 'FASCINATE-2' Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis
Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b 'FASCINATE-2' Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis
Read more →SGMTSagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)
Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)
Read more →SGMTTargeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Read more →SGMTSagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022
Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022
Read more →SGMTSagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022
Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022
Read more →SGMTTherapeutic efficacy of FASN inhibition in preclinical models of HCC
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Read more →SGMTNew Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China
New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China
Read more →SGMTSagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting 2021
Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting 2021
Read more →SGMTSagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
Read more →SGMTPublished Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat
Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat
Read more →SGMTTVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
Read more →SGMTSagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors
Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors
Read more →SGMTSagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress 2021 (EASL)
Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress 2021 (EASL)
Read more →SGMTSagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
Read more →SGMTSagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer
Sagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer
Read more →SGMTFASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
Read more →SGMTSagimet Biosciences Raises $80 Million in Crossover Financing
Sagimet Biosciences Raises $80 Million in Crossover Financing
Read more →SGMTASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
Read more →SGMTSagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting Digital Experience 2020
Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting Digital Experience 2020
Read more →SGMTTVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
Read more →SGMTNovel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
Read more →SGMTFatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
Read more →SGMTSagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640
Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640
Read more →SGMTData on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020
Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that promising clinical
Read more →SGMTFASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study
Read more →SGMT3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways San Mateo, California, August 5, 2019 – 3-V Biosciences, a clinical-stage biotechnology company, announced today that it has changed its name to Sagimet Biosciences
Read more →SGMT3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 – 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of th
Read more →SGMTAscletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an
Read more →SGMT3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017
Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class fatty acid synthase (FASN) inhibitors at the up
Read more →SGMT3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA
Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been selected for a Presidential Poster o
Read more →SGMT3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA
Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three abstracts at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer The
Read more →SGMT3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015
Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Pars
Read more →SGMT3-V Biosciences Provides Clinical Update on TVB-2640 at AACR Metabolism and Cancer Conference
Menlo Park, California, June 9, 2015: 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, is pleased to announce that new data from its ongoing Phase 1 Study of its lead program
Read more →SGMTDiacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells
Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells
Read more →SGMT3-V Biosciences Appoints Rekha Hemrajani as Chief Financial Officer
Menlo Park, California, February 19, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Rekha Hemrajani has joined the Company as its Chief Financial
Read more →SGMT3-V Biosciences Announces Closing of $28.5M Financing Round
Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the closing of its Series D round of financing co-led by NEA, Klein
Read more →SGMT3-V Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
Menlo Park, California, December 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Chief Executive Officer, Merdad Parsey, M.D., Ph.D., will prese
Read more →SGMT3-V Biosciences Announces Presentation of First Human Clinical Data for Lead Oral FASN Inhibitor Candidate at EORTC-NCI-AACR 2014
Barcelona, Spain, November 19, 2014. 3-V Biosciences, Inc., (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, today presented the first human clinical data for its first-in-class lead oncology
Read more →SGMT3-V Biosciences to Present Clinical and Preclinical Data for FASN Inhibitors at EORTC-NCI-AACR 2014
Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, will present clinical data for its lead therapeutic compound, TVB-2640, in a late-bre
Read more →SGMT3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the recent initiat
Read more →SGMT3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the com
Read more →SGMT3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pa
Read more →SGMT3-V Biosciences Completes $20 Million Series C Financing
Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the fi
Read more →SGMT3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infectio
Read more →SGMT3-V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012
Menlo Park, California, October 1, 2012. 3‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9‐13 in Boston,
Read more →SGMT3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Menlo Park, California, July 10, 2012. 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula Hotel in New York City. Dr. Kemble will provide an overview of 3‐V,
Read more →SGMT3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program
Menlo Park, California, January 5, 2012 . 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV). “The continued support of the company’s in
Read more →SGMT3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed produ
Read more →SGMT3-V Biosciences Appoints Dr. George W. Kemble, PhD, as Chief Scientific Officer
Menlo Park, California, August 15, 2011 . 3-V Biosciences, Inc. announced today the appointment of Dr. George W. Kemble, PhD as Chief Scientific Officer. “We are very pleased to have George as the newest member of the 3-V senior management team,” said Merdad V. Parsey, MD, PhD,
Read more →SGMT3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
Menlo Park, California, February 10, 2011 . 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer. “Steve's contributions have been pivotal as a member of the team during his tenure at 3-V,” said Merdad V. Parsey, MD, PhD, 3-V’s Chief Ex
Read more →SGMT3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Menlo Park, California, September 30, 2010 . 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer. We are very pleased to have Merdad as the new CEO of 3-V,” said David M. Mott, 3-V’s Executive Chairman, who is returning t
Read more →SGMTJames F. Young joins 3-V Biosciences Board of Directors
Menlo Park, California, July 20, 2010 . 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. “We are very pleased to welcome Jim Young to the 3-V Board,” said David M. Mott, 3-V’s Executive Chairman. “Jim’s expertise as a viro
Read more →SGMT3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer
Menlo Park, California, June 3, 2010 . 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer. “Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development o
Read more →SGMT3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
Menlo Park, California, May 13, 2010 . 3-V Biosciences, Inc. announced today the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations, the consolidation of all preclinical research under Robert S. McDowell, Ph.D. as Vice Pres
Read more →Competitive Position
How SGMT ranks across every disease it competes inCompetitive Position is a premium feature
See how SGMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial